Drugs / PeptiCRAd-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05492682 | Feb 2023 → Apr 2027 expected | colorectal cancer, cutaneous melanoma, myxoid liposarcoma, non-small cell lung carcinoma +3 | Valo Therapeutics Oy | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PeptiCRAd-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05492682 ↗ |
| Route | Other | “PeptiCRAd-1 will be administered by intratumoral (i.t.) injection (Cohort 1)” NCT05492682 ↗ |